Oren Pasvolsky

Peer-Reviewed Articles

1. Pasvolsky, O, Shimony, S, Saliba, RM, Marcoux, C, Ledesma, C, Rondon, G, Tewari, P, Ragoonanan, D, Short, NJ, Jabbour, EJ, Gooptu, M, Ho, VT, Soiffer, RJ, Antin, JH, Koreth, J, Cutler, C, Paolino, JD, Duncan, C, Lehmann, L, DeAngelo, DJ, Jain, N, Champlin, RE, Shpall, E, Luskin, MR, Kebriaei, P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults With Acute Lymphoblastic Leukemia—A Retrospective, Dual-Center Study. American journal of hematology 101(1):16-25, 2026. e-Pub 2026. PMID: 41051170.
2. Aljawai, YM, Ramdial, JL, Smallbone, PI, Chen, GL, Kebriaei, P, Pasvolsky, O, Popat, UR, Oran, B, Rezvani, K, Champlin, RE, Shpall, E, Mehta, RS. Comparative outcomes of HSCT with posttransplant cyclophosphamide in older adults. Blood Advances 9(20):5201-5206, 2025. e-Pub 2025. PMID: 40795211.
3. Dhakal, B, Akhtar, O, Fandrei, D, Jensen, A, Banerjee, R, Pan, D, Richard, S, Friend, R, Rees, MJ, Costello, P, Vazquez-Martinez, M, Pasvolsky, O, Wagner, C, Davis, JA, Castaneda Puglianini, OA, Reshef, R, Afrough, A, Dima, D, Bhutani, M, Nadeem, O, Parrondo, RD, Freeman, C, Mikkilineni, L, Raza, S, Anderson, L, Kapoor, P, Hosoya, H, Chhabra, S, Grajales-Cruz, A, Gaballa, MM, Midha, S, Alsina, M, Sborov, D, Patel, K, Lin, Y, Ferreri, C, Gagelmann, N, Kumar, A, Hansen, DK, Cowan, AJ, Costa, LM, Merz, M, Sidana, S. Sequential targeting in multiple myeloma. Blood 146(17):2063-2072, 2025. e-Pub 2025. PMID: 40749169.
4. Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
5. Dima D, Logue JM, Waqar SHB, Peres LC, Colin-Leitzinger CM, De Avila G, Smith EC, Skelson L, Matte KL, Blue B, Hovanky VN, Gaballa M, Pasvolsky O, Oswald LB, Fortuna GGM, Wagner CB, DeJarnette S, Dillard C, Perna F, Mikkilineni L, Hosoya H, Freeman CL, Shain KH, Baz RC, Grajales-Cruz A, Puglianini OC, Alsina M, Locke FL, Shune LO, Sborov DW, Patel KK, Sidana S, Hansen DK. Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma. Haematologica 111(1):184-195, 2025. e-Pub 2025. PMID: 40637727.
6. Razzo BM, Midha S, Portuguese AJ, Grajales-Cruz AF, De Menezes Silva Corraes A, Costello P, Liu Y, Sperling AS, Nadeem O, Dima D, Banerjee R, Cowan AJ, Afrough A, Anderson LD, Lieberman-Cribbin A, Kaur G, Goyal A, Atrash S, Ferreri CJ, Voorhees PM, Pasvolsky O, Lee HC, Patel KK, Julian KL, Forsberg PA, Herr MM, Chhabra S, Parrondo RD, Lin Y, Chen A, Susanibar-Adaniya SP, Khouri J, Raza S, Anwer F, Vazquez-Martinez M, Castaneda Puglianini O, Sborov DW, Davis JA, Rossi A, Shune L, Bhurtel J, Hwang WT, Hansen DK, Sidana S, Garfall AL, Richard S. Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium. Blood Cancer Discov 6(6):561-571, 2025. e-Pub 2025. PMID: 40629516.
7. Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, De Avila G, Susaniba Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Castaneda Puglianini O, Rossi A, Lin Y, Atrash S, Sborov D, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson LD Jr, Lee HC, Anwer F, Ferreri CJ, Shune L. Outcomes of teclistamab in patients with relapsed/refractory multiple myeloma with prior exposure to BCMA-directed therapy: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J 15(1):111, 2025. e-Pub 2025. PMID: 40562770.
8. McCurry D, Ge Z, Lee J, Pasumarthi R, Leng X, Koehnke T, Pasvolsky O, Raparla P, Nguyen V, Maurer K, Li S, Livak KJ, Danson E, Thakkar B, Azizi E, Soiffer RJ, Shukla SA, Majeti R, Ritz J, Wu CJ, Molldrem JJ, Bachireddy P. ASXL1 truncating mutations drive leukemic resistance to T cell attack. bioRxiv, 2025. e-Pub 2025. PMID: 40661385.
9. Pasvolsky O, Marcoux C, Milton DR, Rafaeli N, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Deen AF, Aljawai Y, Lee HC, Patel KK, Becnel MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin R, Shpall EJ, Qazilbash MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplant Cell Ther 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
10. Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez M, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni F, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune L, DeJarnette S, Bhurtel E, Susanibar Adaniya S, Portuguese A, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Midha S, Omar N, Atarsh S, McGuirk J, Sborov D, Voorhees P, Anwer F, Alsina M, Freeman C, Garfall AL, Razzo BM, Sidana S, Cowan AJ, Anderson LD Jr, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium. Blood Cancer J 15(1):92, 2025. e-Pub 2025. PMID: 40346049.
11. Dima D, Afrough A, Goel U, Grajales-Cruz A, Khouri J, Julian K, Pasvolsky O, Banerjee R, Razzo B, Ferreri CJ, Vazquez Martinez MA, Davis JA, Sannareddy A, Castaneda Puglianini O, Raza S, Portuguese AJ, Gaballa MR, Rana M, Lieberman-Cribbin A, DeJarnette S, Gonzalez R, Chen A, Herr MM, Mikkilineni L, Hosoya H, Ouchveridze E, Kaur G, Rossi AC, Shune L, Anwer F, Lin Y, Richard S, Sborov DW, Baz RC, Garfall A, Lee HC, Anderson LD Jr, Cowan AJ, Patel KK, Voorhees PM, Sidana S, Hansen DK, Atrash S, Susanibar-Adaniya SP. Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment. Blood Adv 9(14):3408-3417, 2025. e-Pub 2025. PMID: 40198766.
12. Pasvolsky O, Abid MB, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Jatoi A, Khan HN, Lin P, Ramdial J, Nieto Y, Tang G, Siddiqui U, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Gaballa MR, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. Br J Haematol 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
13. Banerjee R, Richards A, Midha S, Afrough A, Anwer F, Atanackovic D, Atrash S, Bachanova V, Beitinjaneh AM, Ouchveridze E, Castaneda Puglianini O, Chhabra S, Cicero KI, Davis JA, Dhakal B, Dima D, Ferreri CJ, Forsberg PA, Freeman CL, Herr MM, Jain T, Janakiram M, Khouri J, Kocoglu MH, Kumar AD, Liu Y, Locke FL, McGuirk JP, Mikkilineni L, Nadeem O, Parrondo RD, Pasvolsky O, Peres LC, Purvey S, Raza S, Reshef R, Richard S, Rossi AC, Sborov DW, Shune L, Wagner CB, Zanwar SS, Sidana S, Patel KK, Hansen DK, Kumar SK, Lin Y, Martin TG, Voorhees PM, Anderson LD Jr, Cowan AJ, Kaur G. Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Adv 9(9):2336-2340, 2025. e-Pub 2025. PMID: 40088469.
14. Pasvolsky O, Marcoux C, Wang Z, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee HC, Patel KK, Becnel MR, Ye C, Kebriaei P, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
15. Smallbone, PI, Shigle, TL, Pasvolsky, O, Hosing, C, Alousi, AM, Bashir, Q, Aljawai, YM, Ramdial, JL, Popat, UR, Champlin, RE, Shpall, E, Oran, B. Maintenance therapy with oral decitabine plus cedazuridine after allogeneic stem cell transplantation for myelodysplastic syndrome. Haematologica 110(8):1798-1807, 2025. e-Pub 2025. PMID: 40013380.
16. Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Asoori Maringanti S, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol 43(13):JCO2401730, 2025. e-Pub 2025. PMID: 39965175.
17. Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplant Cell Ther 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
18. Yeh J, Pasvolsky O, Saliba RM, Figgins B, Wang C, Fang Z, Ahmed S, Yilmaz M, Daver N, Ravandi F, DiNardo C, Short NJ, Kadia T, Al-Atrash G, Daher M, Costa DM, Popat U, Champlin R, Shpall E, Oran B. Efficacy and Safety of Gilteritinib versus Sorafenib as Post-Transplant Maintenance in Patients With FLT3-ITD Acute Myeloid Leukemia. Clin Lymphoma Myeloma Leuk 24(11):e819-e826, 2024. e-Pub 2024. PMID: 39183099.
19. Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Optimal infused CD34(+) cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):189, 2024. e-Pub 2024. PMID: 39482325.
20. Marcoux C, Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Ahmed A, Aljawai Y, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma with Deletion. Transplant Cell Ther:17, 2024.
21. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee HC, Gaballa MR, Patel KK, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplant Cell Ther 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
22. Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Kebriaei P, Aljawai Y, Khan HN, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood Cancer J 14(1):82, 2024. e-Pub 2024. PMID: 38760362.
23. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2024. e-Pub 2024. PMID: 38127583.
24. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. Br J Haematol 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
25. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Marin D, Rondon G, Kebriaei P, Champlin R, Daver N, Dinardo C, Short NJ, Shpall EJ, Oran B. Azacitidine Post-transplant Maintenance Improves Disease Progression in High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Clin Lymphoma Myeloma Leuk 24(5):e196-e204, 2024. e-Pub 2024. PMID: 38403505.
26. Giladi, O, Bagnato, G, Gentilini, M, Shimony, S, Pasvolsky, O, Berger, T, Itchaki, G, Raanani, P, Lolli, G, Stefoni, V, Broccoli, A, Argnani, L, Zinzani, PL, Gurion, R. Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study. Annals of Hematology 103(3):803-811, 2024. e-Pub 2024. PMID: 37950052.
27. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Ther 30(2):205.e1-205.e12, 2024. e-Pub 2024. PMID: 37437764.
28. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood Cancer J 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
29. Pasvolsky O, Marcoux C, Milton DR, Pal B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Becnel MR, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Optimal Infused CD34+ Cell Dose in Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Blood Cancer J, 2024.
30. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
31. Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer 23(1):1258, 2023. e-Pub 2023. PMID: 38124057.
32. Giladi O, Bagnato G, Gentilini M, Shimony S, Pasvolsky O, Berger T, Itchaki G, Raanani P, Lolli G, Stefoni V, Broccoli A, Argnani L, Zinzani PL, Gurion R. Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study. Ann Hematol. e-Pub 2023. PMID: 37950052.
33. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson A, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Saini N, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative fractionated busulfan for allogeneic stem cell transplant in older patients or patients with comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
34. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
35. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged Less than or equal to 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
36. Strati P, Pasvolsky O, Feng L, Xu G, Tewari SO, Varghese J, Ow K, Santiago M, Al Zaki A, Jallouk A, Neelapu SS, Kebriaei P, Shpall EJ, Ahmed S. ASCT vs CART for patients with relapsed LBCL in PR: role of TMTV. Blood Adv 7(11):2586-2589, 2023. e-Pub 2023. PMID: 36745104.
37. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
38. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201(4):e37-e41, 2023. e-Pub 2023. PMID: 36916461.
39. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
40. Yeshurun M, Rozovski U, Shargian L, Pasvolsky O, van der Werf S, Tridello G, Knelange N, Mikulska M, Styczynski J, Averbuch D, de la Camara R. Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey. Bone Marrow Transplant 58(4):414-423, 2023. e-Pub 2023. PMID: 36653669.
41. Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
42. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short NJ, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Am J Hematol 98(2):E35-E37, 2023. e-Pub 2023. PMID: 36502492.
43. Shargian L, Amit O, Bernstine H, Gurion R, Gafter-Gvili A, Rozovski U, Pasvolsky O, Perets G, Horowitz NA, Halloun J, Perry C, Avivi I, Raanani P, Yeshurun M, Ram R. The role of additional chemotherapy prior to autologous HCT in patients with relapse/refractory DLBCL in partial remission-A retrospective multicenter study. Eur J Haematol 110(2):149-156, 2023. e-Pub 2023. PMID: 36251268.
44. Pasvolsky O, Berger T, Geiger KR, Akirov A, Bshara E, Raanani P, Gafter-Gvili A, Shochat T, Rozovski U, Gurion R. Infectious complications and long-term outcomes in patients with diffuse large B-Cell lymphoma and diabetes mellitus. Leuk Lymphoma 63(14):3378-3384, 2022. e-Pub 2022. PMID: 36067523.
45. Berger T, Shacham Abulafia A, Shimony S, Pasvolsky O, Vaxman I, Miron Y, Feldman S, Leader A, Raanani P. Prevalence and Clinical Characteristics of Paraproteinemia Associated with Chronic Myeloid Leukemia. Acta Haematol 145(6):619-626, 2022. e-Pub 2022. PMID: 35908535.
46. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
47. Gover-Proaktor, A, Granot, G, Pasvolsky, O, Raanani, P, Leader, A. CML-074 Pathogenesis of Tyrosine Kinase Inhibitor–Associated Vascular Toxicity in Chronic Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia 22:S286-S287, 2022. e-Pub 2022. PMID: 36163906.
48. Giladi, O, Bagnato, G, Gentilini, M, Shimony, S, Pasvolsky, O, Berger, T, Itchaki, G, Raanani, P, Broccoli, A, Stefoni, V, Lolli, G, Argnani, L, Zinzani, PL, Gurion, R. ABCL-298 Diffuse Large B-Cell Lymphoma During the Covid-19 Pandemic in Two Tertiary Centers. Clinical Lymphoma, Myeloma and Leukemia 22:S370-S371, 2022. e-Pub 2022.
49. Berger T, Geiger KR, Yeshurun M, Gafter-Gvili A, Shochat T, Gurion R, Raanani P, Pasvolsky, O. Repeat biopsy in relapsed or refractory diffuse large B cell lymphoma: a nationwide survey and retrospective study. Leuk Lymphoma 63(10):2461-2468, 2022. e-Pub 2022. PMID: 35634737.
50. Geiger KR, Pasvolsky O, Berger T, Raanani P, Shochat T, Gurion R, Anati T, Groshar D, Gafter-Gvili A, Bernstine H. Effect of steroid treatment on the diagnostic yield of baseline 18f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma. EJNMMI Res 12(1):59, 2022. e-Pub 2022. PMID: 36104603.
51. Pasvolsky O, Popat UR. Unravelling ALL: The Keys to Improved Post-Transplant Survival in Acute Lymphoblastic Leukemia. Transplant Cell Ther 28(8):415-416, 2022. e-Pub 2022. PMID: 35914901.
52. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
53. Afrough A, Pasvolsky O, Ma J, Srour S, Bashir Q, Saini N, Hosing C, Popat UR, Kebriaei P, Delgado R, Ullah MR, Murphy R, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Induction With VCD Versus VRD on the Outcome of Patients With Multiple Myeloma After an Autologous Hematopoietic Stem Cell Transplantation. Transplant Cell Ther 28(6):307.e1-307.e8, 2022. e-Pub 2022. PMID: 35331973.
54. Zoref-Lorenz A, Murakami J, Hofstetter L, Iyer S, Alotaibi AS, Mohamed SF, Miller PG, Guber E, Weinstein S, Yacobovich J, Nikiforow S, Ebert BL, Lane A, Pasvolsky O, Raanani P, Nagler A, Berliner N, Daver N, Ellis M, Jordan MB. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood 139(7):1098-1110, 2022. e-Pub 2022. PMID: 34780598.
55. Pasvolsky O, Shimony S, Ram R, Shimoni A, Shargian L, Avni B, Wolach O, Shochat T, Yerushalmi R, Amit O, Raanani P, Yeshurun M. Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first complete remission after 5-azacitidine and venetoclax: a multicenter retrospective study. Ann Hematol 101(2):379-387, 2022. e-Pub 2022. PMID: 34628534.
56. Yeshurun M, Pasvolsky O, Shargian L, Yahav D, Ben-Zvi H, Rubinstein M, Sela-Navon M, Wolach O, Raanani P, Rozovski U. Humoral serological response to the BNT162b2 vaccine after allogeneic haematopoietic cell transplantation. Clin Microbiol Infect 28(2):303.e1-303.e4, 2022. e-Pub 2022. PMID: 34715348.
57. Geiger, KR, Pasvolsky, O, Berger, T, Raanani, P, Shochat, T, Gurion, R, Anati, T, Groshar, D, Gafter-Gvili, A, Bernstine, H. Effect of steroid treatment on the diagnostic yield of baseline 18f-fluorodeoxyglucose positron emission tomography in aggressive B cell lymphoma. EJNMMI Research 12(1), 2022. e-Pub 2022. PMID: 36104603.
58. Pasvolsky O, Yeshurun M, Fraser R, Estrada-Merly N, Rozovski U, Shargian-Alon L, Assal A, Banerjee R, Bumma N, Gale RP, Hagen P, Holmberg L, Hossain NM, Lazarus HM, Lee C, Mian H, Miller KC, Nathan S, Nagler A, Nishihori T, Parrondo RD, Patel S, Schroeder MA, Usmani SZ, Wang T, Wirk B, Kumar S, Shah N, Qazilbash MH, D'Souza A. Maintenance therapy after second autologous hematopoietic cell transplantation for multiple myeloma. A CIBMTR analysis. Bone Marrow Transplant 57(1):31-37, 2022. e-Pub 2022. PMID: 34608275.
59. Berger, T, Sherman, S, Hayman, L, Wolach, O, Abulafia, AS, Raanani, P, Pasvolsky, O. Skin biopsies in acute myeloid leukemia patients undergoing intensive chemotherapy are safe and effect patient management. Scientific reports 11(1), 2021. e-Pub 2021. PMID: 34099850.
60. Berger, T, Giladi, O, Yahav, D, Ben-Zvi, H, Pasvolsky, O, Shargian-Alon, L, Wolach, O, Rozovski, U, Raanani, P, Yeshurun, M. Diarrheal Morbidity During Hematopoietic Cell Transplantation. Infectious Diseases and Therapy 10(2):1023-1032, 2021. e-Pub 2021. PMID: 33661515.
61. Cohen, YC, Zada, M, Wang, SY, Bornstein, C, David, E, Moshe, A, Li, B, Shlomi-Loubaton, S, Gatt, ME, Gur, C, Lavi, N, Ganzel, C, Luttwak, E, Chubar, E, Rouvio, O, Vaxman, I, Pasvolsky, O, Ballan, M, Tadmor, T, Nemets, A, Jarchowcky-Dolberg, O, Shvetz, O, Laiba, M, Shpilberg, O, Dally, N, Avivi, I, Weiner, A, Amit, I. Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing. Nature medicine 27(3):491-503, 2021. e-Pub 2021. PMID: 33619369.
62. Vaxman I, Visram A, Pasvolsky O, Kumar S, Dispenzieri A, Buadi F, Dingli D, Lacy M, Hayman S, Kyle R, Kapoor P, Leung N, Gonsalves W, Kourelis T, Warsame R, Gertz M. Retroperitoneal involvement with light chain amyloidosis- case series and literature review. Leuk Lymphoma 62(2):316-322, 2021. e-Pub 2021. PMID: 33118418.
63. Pasvolsky, O, Rozental, A, Raanani, P, Gafter-Gvili, A, Gurion, R. R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma. Acta Oncologica 60(6):744-749, 2021. e-Pub 2021. PMID: 33734921.
64. Pasvolsky, O, Shargian, L, Rozovski, U, Wolach, O, Ram, R, Shapira, M, Avni, B, Stepensky, P, Israeli, M, Vidal-Fisher, L, Shpilberg, O, Raanani, P, Yeshurun, M. Eltrombopag for enhancement of platelet engraftment in patients undergoing allogeneic cord blood transplantation. Leukemia and Lymphoma 62(11):2747-2754, 2021. e-Pub 2021. PMID: 34013829.
65. Pasvolsky, O, Rozental, A, Raanani, P, Gafter-Gvili, A, Gurion, R. R-CHOP compared to R-CHOP + X for newly diagnosed diffuse large B-cell lymphoma. Acta Oncologica 60(6):744-749, 2021. e-Pub 2021. PMID: 33734921.
66. Pasvolsky, O, Shimony, S, Yeshurun, M, Shargian, L, Wolach, O, Raanani, P, Gafter-Gvili, A, Gurion, R. Maintenance therapy after allogeneic hematopoietic transplant for acute myeloid leukemia. Acta Oncologica 60(10):1335-1341, 2021. e-Pub 2021. PMID: 34325602.
67. Shimony, S, Yeshurun, M, Wolach, O, Ram, R, Rozovski, U, Shargian, L, Zukerman, T, Amit, O, Bar-On, Y, Krayem, B, Avni, B, Peretz, G, Raanani, P, Pasvolsky, O. Post-transplantation maintenance with sorafenib or midostaurin for FLT3 positive AML patients–a multicenter retrospective observational study. Leukemia and Lymphoma 62(10):2475-2481, 2021. e-Pub 2021. PMID: 33879026.
68. Shargian-Alon L, Wolach O, Rozovski U, Yahav D, Sela-Navon M, Rubinstein M, Oniashvilli N, Pasvolsky O, Raanani P, Yeshurun M. Sequential treatment with FLAG-IDA/treosulfan conditioning regimen for patients with active acute myeloid leukemia. Ann Hematol 99(12):2939-2945, 2020. e-Pub 2020. PMID: 32892274.
69. Ganzel C, Ram R, Gural A, Wolach O, Gino-Moor S, Vainstein V, Nachmias B, Apel A, Koren-Michowitz M, Pasvolsky O, Yerushalmi R, Danylesko I, Cohen Y, Peretz G, Moshe Y, Zektser M, Yeganeh S, Rowe JM, Ofran Y. Venetoclax is safe and efficacious in relapsed/refractory AML. Leuk Lymphoma 61(9):2221-2225, 2020. e-Pub 2020. PMID: 32420775.
70. Yeshurun M, Rozovski U, Pasvolsky O, Wolach O, Ram R, Amit O, Zuckerman T, Pek A, Rubinstein M, Sela-Navon M, Raanani P, Shargian-Alon L. Efficacy of folinic acid rescue following MTX GVHD prophylaxis: results of a double-blind, randomized, controlled study. Blood Adv 4(16):3822-3828, 2020. e-Pub 2020. PMID: 32790844.
71. Uziel O, Lahav M, Shargian L, Beery E, Pasvolsky O, Rozovski U, Raanani P, Yeshurun M. Correction: Premature ageing following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 55(7):1519, 2020. e-Pub 2020. PMID: 32269306.
72. Uziel O, Lahav M, Shargian L, Beery E, Pasvolsky O, Rozovski U, Raanani P, Yeshurun M. Premature ageing following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 55(7):1438-1446, 2020. e-Pub 2020. PMID: 32094417.
73. Pasvolsky O, Heiman L, Popovtzer A, Zimra Y, Rabizadeh E, Barshack I, Mardoukh C, Raanani P, Rozovski U. Genomic analysis of metastatic rhabdomyosarcoma masquerading as acute leukemia. Pathol Res Pract 216(1):152779, 2020. e-Pub 2020. PMID: 31813602.
74. Pasvolsky O, Shepshelovich D, Berger T, Tadmor B, Shochat T, Raanani P, Yahalom V, Gafter-Gvili A. Extended Follow-up of an Educational Intervention Encouraging Appropriate Use of Blood Transfusions. Acta Haematol 143(5):446-451, 2020. e-Pub 2020. PMID: 31752009.
75. Shargian-Alon L, Yahav D, Rozovski U, Dovrat S, Amitai I, Sela-Navon M, Pasvolsky O, Raanani P, Yeshurun M. Human herpes virus 6 reactivation following autologous hematopoietic cell transplantation - a single-center experience. Leuk Lymphoma 60(9):2230-2236, 2019. e-Pub 2019. PMID: 30773083.
76. Pasvolsky O, Morelli O, Rozovski U, Vaturi M, Wolach O, Amitai I, Vaxman I, Ratzon R, Yeshurun M, Kornowski R, Iakobishvilli Z, Raanani P. Anthracycline-Induced Cardiotoxicity in Acute Myeloid Leukemia Patients Who Undergo Allogeneic Hematopoietic Stem Cell Transplantation. Clin Lymphoma Myeloma Leuk 19(7):e343-e348, 2019. e-Pub 2019. PMID: 30948329.
77. Pasvolsky O, Zoref-Lorenz A, Abadi U, Geiger KR, Hayman L, Vaxman I, Raanani P, Leader A. Hemophagocytic lymphohistiocytosis as a harbinger of aggressive lymphoma: a case series. Int J Hematol 109(5):553-562, 2019. e-Pub 2019. PMID: 30850926.
78. Castillo JJ, Itchaki G, Paludo J, Varettoni M, Buske C, Eyre TA, Chavez JC, Shain KH, Issa S, Palomba ML, Pasvolsky O, Simpson D, Talaulikar D, Tam CS, Tedeschi A, Ansell SM, Nayak L, Treon SP. Ibrutinib for the treatment of Bing-Neel syndrome: a multicenter study. Blood 133(4):299-305, 2019. e-Pub 2019. PMID: 30523119.
79. Gover-Proaktor A, Granot G, Pasmanik-Chor M, Pasvolsky O, Shapira S, Raz O, Raanani P, Leader A. Bosutinib, dasatinib, imatinib, nilotinib, and ponatinib differentially affect the vascular molecular pathways and functionality of human endothelial cells. Leuk Lymphoma 60(1):189-199, 2019. e-Pub 2019. PMID: 29741440.
80. Pasvolsky O, Berger T, Bernstine H, Hayman L, Raanani P, Vidal L. Spontaneous Regression of Hodgkin Lymphoma: Case Report and Review of the Literature. Acta Haematol 141(1):14-18, 2019. e-Pub 2019. PMID: 30439716.
81. Yeshurun M, Vaxman I, Shargian L, Yahav D, Bishara J, Pasvolsky O, Wolach O, Lahav M, Gurion R, Magen H, Vidal L, Herscovici C, Peck A, Moshe M, Sela-Navon M, Naparstek E, Raanani P, Rozovski U. Antibacterial prophylaxis with ciprofloxacin for patients with multiple myeloma and lymphoma undergoing autologous haematopoietic cell transplantation: a quasi-experimental single-centre before-after study. Clin Microbiol Infect 24(7):749-754, 2018. e-Pub 2018. PMID: 29208561.
82. Grisariu S, Vaxman I, Gatt M, Elias S, Avni B, Arad A, Pasvolsky O, Raanani P, Paltiel O. Enteroviral infection in patients treated with rituximab for non-Hodgkin lymphoma: a case series and review of the literature. Hematol Oncol 35(4):591-598, 2017. e-Pub 2017. PMID: 27734521.
83. Shargian-Alon L, Pasvolsky O, Raanani P. Thalassemia Major and Intermedia in Patients Older than 35 Years: A Single Center Experience. Isr Med Assoc J 19(12):767-771, 2017. e-Pub 2017. PMID: 29235740.
84. Gover-Proaktor A, Granot G, Shapira S, Raz O, Pasvolsky O, Nagler A, Lev DL, Inbal A, Lubin I, Raanani P, Leader A. Ponatinib reduces viability, migration, and functionality of human endothelial cells. Leuk Lymphoma 58(6):1455-1467, 2017. e-Pub 2017. PMID: 27733071.
85. Shashar M, Chernichovski T, Pasvolsky O, Levi S, Grupper A, Hershkovitz R, Weinstein T, Schwartz IF. Vascular Endothelial Growth Factor Augments Arginine Transport and Nitric Oxide Generation via a KDR Receptor Signaling Pathway. Kidney Blood Press Res 42(2):201-208, 2017. e-Pub 2017. PMID: 28478454.
86. Perl L, Pasvolsky O, Lifshitz L, Mekori YA, Hershko AY. Increased eosinophilic responses in splenectomized patients. Ann Allergy Asthma Immunol 108(1):34-38, 2012. e-Pub 2012. PMID: 22192963.
87. Goldin Y, Pasvolsky O, Rogowski O, Shapira I, Steinvil A, Halpern P, Serov J, Deutsch V, Aviram G, Berliner S. The diagnostic yield of D-Dimer in relation to time from symptom onset in patients evaluated for venous thromboembolism in the emergency medicine department. J Thromb Thrombolysis 31(1):1-5, 2011. e-Pub 2011. PMID: 20419335.

Review Articles

1. Pasvolsky O, Kebriaei P, Shah BD, Jabbour E, Jain N. Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead. Blood Adv 7(14):3350-3360, 2023. e-Pub 2023. PMID: 36912764.
2. Pasvolsky O, Daher M, Alatrash G, Marin D, Daver N, Ravandi F, Rezvani K, Shpall E, Kebriaei P. CARving the Path to Allogeneic CAR T Cell Therapy in Acute Myeloid Leukemia. Front Oncol 11:800110, 2021. e-Pub 2021. PMID: 35083154.
3. Pasvolsky O, Leader A, Iakobishvili Z, Wasserstrum Y, Kornowski R, Raanani P. Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia. Cardiooncology 1(1):5, 2015. e-Pub 2015. PMID: 33530148.
4. Wasserstrum Y, Kornowski R, Raanani P, Leader A, Pasvolsky O, Iakobishvili Z. Hypertension in cancer patients treated with anti-angiogenic based regimens. Cardiooncology 1(1):6, 2015. e-Pub 2015. PMID: 33530150.

Other Articles

1. Hansen DK, Peres LC, Dima D, Richards A, Shune L, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Bhurtel E, McGuirk J, Wagner C, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, De Avila G, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa M, Herr MM, Forsberg P, Janakiram M, Htut M, Maringanti SA, Kalariya N, Hashmi H, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees P, Anderson LD Jr, Richard S, Martin T, Lin Y, Patel KK, Sidana S Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma. J Clin Oncol 43(11):1399, 2025. PMID: 40053892.

Editorials

1. Pasvolsky O, Bashir Q. Autologous transplant and second malignancies in MM. Blood Adv 7(12):2731-2732, 2023. PMID: 37318936.

Abstracts

1. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Aljawai Y, Khan HN, Kebriaei P, Lee H, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience. 65th ASH Annual Meeting, 2023. e-Pub 2023.
2. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. 65th ASH Annual Meeting, 2023. e-Pub 2023.
3. Pasvolsky O, Hildebrandt M, Subramanian N, Ferreri CJ, Lee HC, Manasanch EE, Thomas SK, Weber DM, Gaballa M, Dillard C, Becnel M, Hosing C, Lin P, Amini B, Qazilbash M, Orlowski RZ, Patel KK. Safety and Efficacy Outcomes for Patients with High-Risk Multiple Myeloma Receiving Idecabtagene Vicleucel: The MD Anderson Experience. 65th ASH Annual Meeting, 2023. e-Pub 2023.
4. Pasvolsky O, Shimony S, SalibaRM, Ledesma C, Rondon G, Tewari P, Ragoonanan D, Short NJ, Jabbour E, Gooptu M, Ho VT, Soiffer RJ, Antin JH, Koreth J, Cutler CS, Paolino JD, Duncan CN, Lehmann LE, DeAngelo DJ, Kantarjian H, Champlin R, Shpall E, Luskin MR, Kebriaei P. Allogeneic Hematopoietic Stem Cell Transplantation in Adolescents and Young Adults with Acute Lymphoblastic Leukemia – Retrospective Dual-Center Study. 65th ASH Annual Meeting, 2023. e-Pub 2023.
5. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation. 65th ASH Annual Meeting, 2023. e-Pub 2023.
6. Pasvolsky O, Marcoux C, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee H, Patel KK, Kebriaei P, Tewari P, Thomas SK, Weber DM, Orlowski RZ, Crawford-Suber L, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Young Adults (Aged ≤40 Years) with Newly Diagnosed Multiple Myeloma after Upfront Autologous Stem Cell Transplant. 28th Congress of the European Hematology Association, 2023. e-Pub 2023.
7. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee H, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplant in Patients with Multiple Myeloma with two or more High-Risk Cytogenetic abnormalities. 28th Congress of the European Hematology Association, 2023. e-Pub 2023.
8. Pasvolsky O, Patel KK, Bashir Q, Rauf M, Sui D, Srour S, Tanner M, Popat U, Saini N, Hosing C, Ramdial J, Manasanch E, Lee H, Kaufman G, Thomas SK, Weber DM, Becnel M, Tang G, Orlowski RZ, Patel D, Champlin RE, Nieto Y, Shpall EJ, Qazilbash MH. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. 28th Congress of the European Hematology Association, 2023. e-Pub 2023.
9. Pasvolsky O, Milton DR, Masood A, Shehzad SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas KS, Weber DM, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. 64th ASH Annual Meeting, 2022. e-Pub 2022.
10. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Shpall EJ, Champlin R, Lin P, Qazilbash MH. Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. 64th ASH Annual Meeting, 2022. e-Pub 2022.
11. Pasvolsky O, Saliba RM, Ledesma C, Popat UR, Alousi A, Olson A, Oran B, Hosing C, Bashir Q, Qazilbash MH, Short N, Ravandi F, Champlin R, Shpall EJ, Kebriaei P. Prognostic Significance of Measurable Residual Disease for Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Stem Cell Transplant in Second Complete Remission and Beyond. 64th ASH Annual Meeting, 2022. e-Pub 2022.
12. Pasvolsky O, Saliba RM, Popat UR, Alousi A, Mehta R, Yeh J, Al-Atrash G, Adeel M, Ramdial J, Rondon G, Kebriaei P, Champlin R, Shpall EJ, Oran B. Efficacy of Azacitidine Post-transplant Maintenance for FLT3-negative Acute Myeloid Leukemia and Myelodysplastic Syndrome. 64th ASH Annual Meeting, 2022. e-Pub 2022.
13. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. 27th Congress of the European Hematology Association, 2022. e-Pub 2022.
14. Pasvolsky O, Fraser R, Estrada-Merly N, Yeshurun M, Rozovski U, Shargian-Alon L, Kumar S, Shah N, Qazilbash MH, D'Souza A. Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study. American Society of Clinical Oncology (ASCO) 2021, 2021. e-Pub 2021.
15. Pasvolsky O, Shepshelovich D, Berger T, Tadmor B, Shochat T, Raanani P, Yahalom V, Gafter-Gvili A. Educational intervention encouraging appropriate use of blood transfusions – extended follow up and comparative study. 24th Congress of the European Hematology Association, 2019. e-Pub 2019.
16. Pasvolsky O, Akirov A, Alias B, Raanani P, Gurion R, Rozovski U. The clinical characteristics and outcomes of patients with diffuse large B cell lymphoma and diabetes mellitus. 24th Congress of the European Hematology Association, 2019. e-Pub 2019.
17. Pasvolsky O. Talquetamab for relapsed/refractory multiple myeloma : Real-world outcomes from the US multiple myeloma immunotherapy consortium. ASH 2025.
18. Pasvolsky O. Long-Term Responders After Upfront Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma. Tandem Meeting.
19. Pasvolsky O, Abid MB, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Jatoi A, Khan HN, Lin P, Ramdial J, Nieto Y, Tang G, Siddiqui U, Aljawai Y, Kebriaei P, Lee HC, Patel KK, Gaballa MR, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. EHA 2024 206(6):1730-1736. PMID: 40159289.
20. Pasvolsky O, Marcoux C, Milton DR, Pa B, Tanner MR, Bashir Q, Srour S, Lee J, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Aljawai Y, Kebriaei P, Lee HC, KPatel K, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. ASSOCIATION BETWEEN INFUSED CD34+ CELL DOSE AND OUTCOMES IN AUTOHCT FOR NEWLY DIAGNOSED MULTIPLE MYELOMA“. EHA 2024 8(1):2387-2389.
21. Lu R, Chen J, Ow K, Hildebrandt M, Huen A, Cardoso R, Chambers M, Abreu M, Cuellar E, Ighovoyivwi E, Knight S, Santiago M, Savoie C, Varghese J, Zachariah A, Becnel M, Gaballa M, Orlowski R, Patel K, Pasvolsky O, Thomas S, Ye JC, Weber D, Lee H, Richards T. Evaluation of Clinical Outcomes and Toxicities in Multiple Myeloma Patients Receiving Commercial Talquetamab. IMS 2024.
22. Aljawai Y, Pasvolsky O, Patel K, Bashir Q, Sui D, Srour S, Tanner M, Popat U, Saini N, Hosing C, Ramdial J, Lee H, Kaufman G, Thomas S, Weber D, Becnel M, Tang G, Orlowski R, Patel D, Champlin R, Nieto Y, Shpall E, Qazilbash M. Daratumumab-Based Maintenance in Patients with Relapsed Multiple Myeloma after Salvage Autologous Hematopoietic Stem Cell Transplantation. IMS 2024.
23. Pasvolsky O, Milton D, Rafaeli N, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi A, Aljawai Y, Lee H, Patel K, Kebriaei P, Thomas S, Orlowski R, Shpall E, Champlin R, Qazilbash M. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing an Autologous Transplant. IMS 2024.
24. Pasvolsky O, Wang Z, Milton D, Pal B, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Syed N, Aljawai Y, Lee H, Patel K, Kebriaei P, Thomas S, Orlowski R, Shpall E, Champlin R, Qazilbash M. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. IMS 2024.
25. Dillard C, Hildebrandt M, Lee H, Kalariya N, Subramanian N, Pasvolsky O, Ferreri C, Gaballa M, Thomas S, Weber D, Becnel M, Kaufman G, Chen J, Hawkins M, Abreu M. Impact of Genetic Ancestry on Outcomes and Toxicity of Idecel in Patients with Relapsed/ Refractory Multiple Myeloma (RRMM). IMS 2024.
26. Marcoux C, Pasyar S, Milton D, Khan H, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee H, Patel K, Tang G, Lee J, Aljawai Y, Kebriaei P, Thomas S, Orlowski R, Shpall E, Champlin R, Qazilbash M, Pasvolsky O. Impact of Obesity on Outcomes of Multiple Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant. IMS 2024.
27. Razzo B, Grajales‑Cruz A, Atrash S, Ferreri C, Goyal A, Pasvolsky O, Banerjee R, Julian K, Forsberg P, Herr M, Lin Y, Susanibar‑Adaniya S, Khouri J, Vazquez‑Martinez M, Lee H, Portuguese A, Sborov DW, Dima D, Davis J, Kaur G, Shune L, Hansen D, Sidana S, Garfall A, Richard S. Real-World Experience with Teclistamab for Relapsed/ Refractory Multiple Myeloma from the U.S. Myeloma Immunotherapy Consortium. IMS 2024.
28. Rejeski K, Hansen DK, Dos Santos DMC, Silva Corraes ADM, Castaneda O, Dillard CM, Alsdorf W, Frenking JH, Purcarea A, Chhabra S, Freeman CL, Friedrich MJ, Gaballa MR, Gonzalez R, Bin Waqar SH, Hwa YL, Jain MD, Parrondo RD, Pasvolsky O, Shahbaz W, Shouval R, Spiess G, Stephens H, Theurich S, Bassermann F, Hecker JS, Raab MS, Weisel KC, Locke FL, Subklewe M, Patel KK, Lin Y. Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma. ASH.
29. Dang M, Seif S, Acevedo-Calado MJ, Wang L, Gabriel B, Lewis LS, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Weber DM, Ye J, Orlowski RZ, Thomas SK. Characterization of Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma Using Single Cell Transcriptomic Analysis. ASH.
30. Dima D, Vazquez-Martinez MA, Davis JA, Goel U, Afrough A, Sannareddy A, Pasvolsky O, Razzo B, Banerjee R, Khouri J, Grajales-Cruz A, Lieberman-Cribbin A, Rana MS, Julian K, DeJarnette S, Portuguese AJ, Gaballa MR, Avila GD, Susanibar-Adaniya S, Raza S, Herr MM, Ouchveridze E, Richards T, Hosoya H, Mikkilineni L, Kaur G, Schrum D, Castaneda O, Rossi A, Lin C, Forsberg PA, Lin Y, Atrash S, Sborov DW, Shain KH, Voorhees PM, Richard S, Garfall AL, Hansen DK, Sidana S, Patel KK, Cowan AJ, Anderson Jr LD, Lee HC, Anwer F, Ferreri C, Shune LO. Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. ASH.
31. Banerjee R, Richards A, Khouri J, Janakiram M, Cicero KI, Dima D, Kocoglu MH, Shune LO, Ouchveridze E, Jain T, Afrough A, Zanwar S, Ferreri C, Pasvolsky O, Mikkilineni L, Purvey S, Peres LC, Freeman CL, Midha S, Beitinjaneh A, Davis JA, Wagner CB, Herr MM, Forsberg PA, Sborov DW, Richard S, Reshef R, Dhakal B, Bachanova V, McGuirk JP, Voorhees PM, Anderson Jr LD, Lin Y, Martin TG, Sidana S, Patel KK, Hansen DK, Cowan AJ, Kaur G. Post-CAR-T Driving Restrictions after Week 4 Appear Unnecessary: Data from the United States Myeloma Immunotherapy Consortium. ASH.
32. Dhakal B, Slade M, Narra R, Mohamed ME, Akhtar OS, Bansal H, Acevedo-Calado MJ, Pasvolsky O, Gaballa MR, Becnel MR, Weber DM, Patel KK, Thomas SK, Ye J, Kuhr F, Dong B, Powell S, Bui T, Mohan M, Pasquini MC, D'Souza A, Knysh H, Orlowski RZ, Albitar M, Lee HC. Clearance of Circulating Multiple Myeloma Cells to Assess Early Response to Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma. ASH.
33. Cervoni Curet FN, Bassett RL, Pasvolsky O, Deen AF, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee, HC, Patel KK, Kebriaei P, Fingrut WB, Smallbone P, Becnel MR, Gaballa MR, Thomas SK, Ye J, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. ASH.
34. Pasvolsky O, Afrough A, Feng L, Dong W, Richards T, Davis JA, Dima D, Grajales-Cruz A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Forsberg PA, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Eberwein E, Lin C, Blue B, Raza S, Lin Y, McGuirk JP, Atrash S, Sborov DW, Voorhees PM, Anwer F, Hansen DK, Patel KK, Sidana S, Cowan AJ, Anderson Jr LD, Richard S, Garfall AL, Lee HC, Khouri J. Predictors and Characterization of Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) in Patients with Multiple Myeloma Receiving Teclistamab. ASH.
35. Pasvolsky O, Dima D, Feng L, Dong W, Richards T, Davis JA, Afrough A, Vazquez-Martinez MA, Sannareddy A, Goel U, Banerjee R, Khouri J, Cervoni Curet FN, Gaballa MR, Lieberman-Cribbin A, Rana MS, Julian K, Ferreri CJ, Shune LO, DeJarnette S, Ouchveridze E, Susanibar-Adaniya S, Portuguese AJ, Hosoya H, Mikkilineni L, Kaur G, Rossi A, Herr MM, Schrum D, Lin C, Raza S, Lin Y, Atrash S, McGuirk JP, Sborov DW, Voorhees PM, Anwer F, Alsina M, Freeman CL, Garfall AL, Sidana S, Cowan AJ, Anderson Jr LD, Hansen DK, Richard S, Patel KK, Lee HC, Grajales-Cruz A. Outcomes of Elderly Patients with Relapsed Refractory Multiple Myeloma (RRMM) Treated with Teclistamab: A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium. ASH.
36. Dhakal B, Akhtar OS, Cowan AJ, Richard S, Friend R, Rees MJ, Costello P, Martinez MV, Pasvolsky O, Wagner CB, Jensen A, Davis JA, Reshef R, Dima D, Banerjee R, Bhutani M, Nadeem O, Parrondo RD, Mikkilineni L, Raza S, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Hansen DK, Costa LJ, Sidana S. Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM). ASH.
37. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai YM, Ahmed S, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant. ASH.
38. Lionel A, Seif S, Sun X, Feng L, Gensini L, Gabriel B, Lewis LS, Bansal H, Becnel MR, Gaballa MR, Lee HC, Pasvolsky O, Patel KK, Ye J, Patel KP, Weber DM, Orlowski RZ, Thomas SK. Prognostic Significance of TP53 Mutations in Lymphoplasmacytic Lymphoma. ASH.
39. Hansen DK, Peres LC, Dima D, Richards A, Shune LO, Afrough A, Midha S, Dhakal B, Kocoglu MH, Atrash S, Ferreri C, Castaneda O, Davis JA, Ouchveridze E, McGuirk JP, Wagner CB, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, Avila GD, Purvey S, Hosoya H, Mikkilineni L, Oswald LB, Kaur G, Pasvolsky O, Gaballa MR, Herr MM, Forsberg PA, Janakiram M, Htut M, Asoori S, Kalariya N, Hashmi HS, Reshef R, Sborov DW, Nadeem O, Anwer F, Khouri J, Raza S, Atanackovic D, Alsina M, Freeman CL, Locke FL, Voorhees PM, Anderson Jr LD, Richard S, Martin T, Lin Y, Patel KK, Sidana S. Comparative Safety and Efficacy of Ciltacabtagene Autoleucel and Idecabtagene Vicleucel CAR T-Cell Therapies in Relapsed or Refractory Multiple Myeloma. ASH.
40. Ye J, Tang G, Pasvolsky O, Becnel MR, Gaballa MR, Patel KK, Lee HC, Thomas SK, Weber DM, Lin P, Orlowski RZ. Unveiling Clinical Potential: Exploring Cytogenomic Aberrations through Optical Genomic Mapping in Multiple Myeloma. ASH.
41. Peres LC, Richards A, Sidana S, Oswald LB, Dima D, Afrough A, Shune LO, Midha S, Castaneda O, Ferreri C, Davis JA, Pasvolsky O, Dillard CM, Herr MM, Kocoglu MH, Atrash S, Blue B, Ouchveridze E, McGuirk JP, Wagner CB, Bansal R, Costello P, Smith K, Lieberman-Cribbin A, Avila GD, Purvey S, Hosoya H, Mikkilineni L, Kaur G, Gaballa MR, Forsberg PA, Freeman CL, Janakiram M, Htut M, Asoori S, Kalariya N, Atanackovic D, Dhakal B, Khouri J, Raza S, Reshef R, Alsina M, Locke FL, Nadeem O, Anwer F, Anderson Jr LD, Richard S, Lin Y, Martin T, Voorhees PM, Patel KK, Hansen DK, Sborov DW. Racial and Ethnic Differences in Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel or Ciltacabtagene Autoleucel. ASH.
42. Dang M, Lee HC, Bansal H, Acevedo-Calado MJ, Qin L, Tan W, Moreno Rueda LY, Berrios D, Pasvolsky O, Gaballa MR, Becnel MR, Ye J, Patel KK, Lin P, Thomas SK, Weber DM, Wang L, Orlowski RZ. Multi-Omic Single-Cell Characterization of Paired and Serial Samples in Responding and Non-Responding Patients Receiving BCMA Bispecific Antibody Therapy for Multiple Myeloma. ASH.
43. Ahmed S, Marcoux C, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Deeba R, Tang G, Aljawai Y, Lee H, Patel K, Gaballa M, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M, Pasvolsky O. Outcomes of Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant Following VRD or KRD Induction Therapy. IMS 2025 25(2):S304-S305.
44. Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee H, Ye JC, Patel K, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M. DVRD Induction Followed by Autologous Hematopoietic Stem Cell Transplantation for Older Patients with Multiple Myeloma. IMS 2025 25(2):S304.
45. Pasvolsky O, Milton D, Haider A, Tanner M, Bashir Q, Srour S, Saini N, Smallbone P, Lin P, Ramdial J, Nieto Y, Mohamedi A, Siddiqui U, Tang G, Aljawai Y, Lee H, Patel K, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M. Delayed or Salvage Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. IMS 2025 25(2):s344-s345.
46. Mikulski D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee H, Patel K, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M, Pasvolsky O. Monosomy 13 and Deletion of 13q Predict Inferior Outcomes in Multiple Myeloma Patients Undergoing Upfront Autologous Transplant. IMS 2025 25(2):S199.
47. Pasvolsky O, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Lee H, Ye JC, Patel K, Kebriaei P, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M. DKRD vs. DVRD Induction Prior to Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. IMS 2025 25(2):S304.

Book Chapters

1. Gutierrez C, Pasvolsky O, Kebriaei P. CAR T-Cell Therapy and Critical Care Considerations. In: Pulmonary and Critical Care Considerations of Hematopoietic. Springer, Cham, 427-435, 2023.
2. Pasvolsky O, Ulmansky R, Naparstek Y, Hershko AY. Anti-collagen antibodies. In: Autoantibodies. 3rd. Elsevier, 717-722, 2014.

Letters to the Editor

1. Banerjee, R, Kaur, G, Razzo, BM, Portuguese, AJ, Sidana, S, Richards, TA, Grajales-Cruz, A, Richard, S, Shune, L, Khouri, J, Dima, D, Lee, HC, Patel, K, Pasvolsky, O, Vazquez-Martinez, M, Hansen, DK, Afrough, A, Davis, JA, Hashmi, H, Atrash, S, Ferreri, C, Julian, K, Herr, M, Midha, S, Costello, P, Forsberg, P, de Menezes Silva Corraes, A, Lin, Y, Cowan, AJ, Anderson, L, Garfall, A. Predictors of Delayed Responses to Teclistamab in Multiple Myeloma After Initial Non-Response. American journal of hematology 101: 169-173, 2026.
2. Chohan, KL, Gensini, L, Seif, S, Sun, X, Feng, L, Becnel, M, Gaballa, MM, Lee, HC, Pasvolsky, O, Patel, K, Ye, JC, Weber, DM, Orlowski, R, Thomas, SK. Long-term outcomes and treatment patterns in Waldenström macroglobulinemia patients who discontinue Bruton tyrosine kinase inhibitor (BTKi) therapy. Blood cancer journal 15, 2025.
3. Marcoux C, Pasyar S, Milton DR, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Neupane N, Lee HC, Patel KK, Tang G, Aljawai Y, Kebriaei P, Thomas SK, Orlowski RZ, Shpall EJ, Champlin R, Qazilbash MH, Pasvolsky O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. Br J Haematol 206: 763-765, 2025.
4. Zanwar S, Sidana S, Shune L, Puglianini OC, Pasvolsky O, Gonzalez R, Dima D, Afrough A, Kaur G, Davis JA, Herr M, Hashmi H, Forsberg P, Sborov D, Anderson LD Jr, McGuirk JP, Wagner C, Lieberman-Cribbin A, Rossi A, Freeman CL, Locke FL, Richard S, Khouri J, Lin Y, Patel KK, Kumar SK, Hansen DK. Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel. J Hematol Oncol 17: 42, 2024.